Cargando…

Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort

BACKGROUND: Anti-CD74 IgG antibodies are reported to be elevated in patients with axial spondyloarthritis (axSpA). This study assessed the diagnostic value of anti-CD74 antibodies in patients with early axSpA. METHODS: Anti-CD74 IgG and IgA antibodies were first measured in an exploratory cohort of...

Descripción completa

Detalles Bibliográficos
Autores principales: de Winter, Janneke J., van de Sande, Marleen G., Baerlecken, Niklas, Berg, Inger, Ramonda, Roberta, van der Heijde, Désirée, van Gaalen, Floris A., Witte, Torsten, Baeten, Dominique L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831708/
https://www.ncbi.nlm.nih.gov/pubmed/29490705
http://dx.doi.org/10.1186/s13075-018-1535-x
_version_ 1783303186733334528
author de Winter, Janneke J.
van de Sande, Marleen G.
Baerlecken, Niklas
Berg, Inger
Ramonda, Roberta
van der Heijde, Désirée
van Gaalen, Floris A.
Witte, Torsten
Baeten, Dominique L.
author_facet de Winter, Janneke J.
van de Sande, Marleen G.
Baerlecken, Niklas
Berg, Inger
Ramonda, Roberta
van der Heijde, Désirée
van Gaalen, Floris A.
Witte, Torsten
Baeten, Dominique L.
author_sort de Winter, Janneke J.
collection PubMed
description BACKGROUND: Anti-CD74 IgG antibodies are reported to be elevated in patients with axial spondyloarthritis (axSpA). This study assessed the diagnostic value of anti-CD74 antibodies in patients with early axSpA. METHODS: Anti-CD74 IgG and IgA antibodies were first measured in an exploratory cohort of patients with radiographic axSpA (138 patients with ankylosing spondyloarthritis (AS)) and 57 healthy controls and then were measured in patients with early axSpA (n = 274) and with non-SpA chronic back pain (CBP) (n = 319), participating in the spondyloarthritis caught early (SPACE) prospective cohort study of patients under 45 years old with early back pain (for ≥ 3 months, but ≤ 2 years). RESULTS: In the exploratory cohort, anti-CD74 IgG antibodies were present in 79.7% of patients with AS vs. 43.9% of healthy controls (p < 0.001). Anti-CD74 IgA antibodies were present in 28.5% of patients with AS vs. 5.3% of healthy controls (p < 0.001). In the SPACE cohort, anti-CD74 IgG antibody levels were present in 46.4% of the patients with axSpA vs. 47.9% of the patients with CBP (p = 0.71). Anti-CD74 IgA antibodies were present in 54.7% of the patients with axSpA and 37.0% of the patients with CBP (p < 0.001). This resulted in a positive predictive value of 58.8% (compared to a prior probability of 46.2%) and a negative predictive value of 59.1% (compared to a prior probability of 53.8%). In a regression model, total serum IgA was associated with axSpA odds ratio (OR) 1.19, p < 0.001) whereas anti-CD74 IgA was not (OR) 1.01, p = 0.33). Furthermore, anti-CD74 IgA was associated with sacroiliitis on magnetic resonance imaging (MRI) (OR) = 2.50, p = 0.005) and heel enthesitis (OR) = 2.56, p = 0.002). CONCLUSIONS: Albeit anti-CD74 IgA is elevated in patients with early axSpA, this elevation is not sufficiently specific to yield significant diagnostic value in patients under 45 years old presenting with early back pain.
format Online
Article
Text
id pubmed-5831708
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58317082018-03-05 Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort de Winter, Janneke J. van de Sande, Marleen G. Baerlecken, Niklas Berg, Inger Ramonda, Roberta van der Heijde, Désirée van Gaalen, Floris A. Witte, Torsten Baeten, Dominique L. Arthritis Res Ther Research Article BACKGROUND: Anti-CD74 IgG antibodies are reported to be elevated in patients with axial spondyloarthritis (axSpA). This study assessed the diagnostic value of anti-CD74 antibodies in patients with early axSpA. METHODS: Anti-CD74 IgG and IgA antibodies were first measured in an exploratory cohort of patients with radiographic axSpA (138 patients with ankylosing spondyloarthritis (AS)) and 57 healthy controls and then were measured in patients with early axSpA (n = 274) and with non-SpA chronic back pain (CBP) (n = 319), participating in the spondyloarthritis caught early (SPACE) prospective cohort study of patients under 45 years old with early back pain (for ≥ 3 months, but ≤ 2 years). RESULTS: In the exploratory cohort, anti-CD74 IgG antibodies were present in 79.7% of patients with AS vs. 43.9% of healthy controls (p < 0.001). Anti-CD74 IgA antibodies were present in 28.5% of patients with AS vs. 5.3% of healthy controls (p < 0.001). In the SPACE cohort, anti-CD74 IgG antibody levels were present in 46.4% of the patients with axSpA vs. 47.9% of the patients with CBP (p = 0.71). Anti-CD74 IgA antibodies were present in 54.7% of the patients with axSpA and 37.0% of the patients with CBP (p < 0.001). This resulted in a positive predictive value of 58.8% (compared to a prior probability of 46.2%) and a negative predictive value of 59.1% (compared to a prior probability of 53.8%). In a regression model, total serum IgA was associated with axSpA odds ratio (OR) 1.19, p < 0.001) whereas anti-CD74 IgA was not (OR) 1.01, p = 0.33). Furthermore, anti-CD74 IgA was associated with sacroiliitis on magnetic resonance imaging (MRI) (OR) = 2.50, p = 0.005) and heel enthesitis (OR) = 2.56, p = 0.002). CONCLUSIONS: Albeit anti-CD74 IgA is elevated in patients with early axSpA, this elevation is not sufficiently specific to yield significant diagnostic value in patients under 45 years old presenting with early back pain. BioMed Central 2018-03-01 2018 /pmc/articles/PMC5831708/ /pubmed/29490705 http://dx.doi.org/10.1186/s13075-018-1535-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
de Winter, Janneke J.
van de Sande, Marleen G.
Baerlecken, Niklas
Berg, Inger
Ramonda, Roberta
van der Heijde, Désirée
van Gaalen, Floris A.
Witte, Torsten
Baeten, Dominique L.
Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort
title Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort
title_full Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort
title_fullStr Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort
title_full_unstemmed Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort
title_short Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort
title_sort anti-cd74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (space) cohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831708/
https://www.ncbi.nlm.nih.gov/pubmed/29490705
http://dx.doi.org/10.1186/s13075-018-1535-x
work_keys_str_mv AT dewinterjannekej anticd74antibodieshavenodiagnosticvalueinearlyaxialspondyloarthritisdatafromthespondyloarthritiscaughtearlyspacecohort
AT vandesandemarleeng anticd74antibodieshavenodiagnosticvalueinearlyaxialspondyloarthritisdatafromthespondyloarthritiscaughtearlyspacecohort
AT baerleckenniklas anticd74antibodieshavenodiagnosticvalueinearlyaxialspondyloarthritisdatafromthespondyloarthritiscaughtearlyspacecohort
AT berginger anticd74antibodieshavenodiagnosticvalueinearlyaxialspondyloarthritisdatafromthespondyloarthritiscaughtearlyspacecohort
AT ramondaroberta anticd74antibodieshavenodiagnosticvalueinearlyaxialspondyloarthritisdatafromthespondyloarthritiscaughtearlyspacecohort
AT vanderheijdedesiree anticd74antibodieshavenodiagnosticvalueinearlyaxialspondyloarthritisdatafromthespondyloarthritiscaughtearlyspacecohort
AT vangaalenflorisa anticd74antibodieshavenodiagnosticvalueinearlyaxialspondyloarthritisdatafromthespondyloarthritiscaughtearlyspacecohort
AT wittetorsten anticd74antibodieshavenodiagnosticvalueinearlyaxialspondyloarthritisdatafromthespondyloarthritiscaughtearlyspacecohort
AT baetendominiquel anticd74antibodieshavenodiagnosticvalueinearlyaxialspondyloarthritisdatafromthespondyloarthritiscaughtearlyspacecohort